“…Doxorubicin is a well-established and highly effective anti-neoplastic agent that is used to treat several adult and paediatric cancers such as solid tumours, leukaemia, lymphomas, and breast cancer (Carvalho et al, 2009 ; Octavia et al, 2012 ). The successful use of doxorubicin has been hampered by its toxicity to numerous organs such as the heart (Yilmaz et al, 2006 ; Carvalho et al, 2009 ; Rashid et al, 2013 ; Indu et al, 2014 ; Afsar et al, 2017 ; Bordbar et al, 2019 ; Ikewuchi et al, 2021a ), liver (Carvalho et al, 2009 ; Indu et al, 2014 ; Chen et al, 2016 ; Alghorabi et al, 2019 ; Ikewuchi et al, 2021b ), kidneys (Yilmaz et al, 2006 ; Carvalho et al, 2009 ; Rashid et al, 2013 ; Ren et al, 2016 ; Bordbar et al, 2019 ; Sabapathy et al, 2019 ; Ikewuchi et al, 2021c ), and lungs (Vapa et al, 2012 ; Jagetia and Lalrinpuii, 2018 ). Hepatonephrotoxicity induced by doxorubicin is accompanied by increased plasma levels of creatinine, urea, uric acid, gamma-glutamyl transferase, lactate dehydrogenase, alanine transaminase, aspartate transaminase, and alkaline phosphatase and decreased plasma albumin and total protein levels (Öz and İlhan, 2006 ; Yilmaz et al, 2006 ; Lee et al, 2013 ; Ahmed et al, 2019a ).…”